Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AGRX Agile Therapeutics (AGRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipSustainabilityTrends About Agile Therapeutics Stock (NASDAQ:AGRX) 30 days 90 days 365 days Advanced Chart Ad Timothy SykesPrepare Now Before This Looming $2 Trillion D.C. ShockMillions of traders could get blindsided by this election-year shock on December 18th… And if you do nothing now, you could wind up panicking in the next 30 days… or worse, making a costly mistake.Click here to watch his emergency briefing >>> Get Agile Therapeutics alerts:Sign Up Key Stats Today's Range$1.51▼$1.5250-Day Range$1.43▼$1.5152-Week Range$0.20▼$2.63Volume120,900 shsAverage Volume352,864 shsMarket Capitalization$10.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewAgile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.Read More… Receive AGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AGRX Stock News HeadlinesAgile Therapeutics, Inc.: Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.August 27, 2024 | finanznachrichten.deAgile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.August 26, 2024 | globenewswire.comPrepare Now Before This Looming $2 Trillion D.C. ShockMillions of traders could get blindsided by this election-year shock on December 18th… And if you do nothing now, you could wind up panicking in the next 30 days… or worse, making a costly mistake.December 12, 2024 | Timothy Sykes (Ad)Agile Leadership for Pharma and Biopharma Professionals in a Hybrid World: 2-Day Training Course (Online) November 18-19, 2024 - Become Competent and Familiar in a Range of Well-Recognised Leadership TechniquesAugust 7, 2024 | globenewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Agile Therapeutics, Inc. - AGRXJuly 3, 2024 | prnewswire.comAGRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Agile Therapeutics, Inc. Is Fair to ShareholdersJune 26, 2024 | businesswire.comAgile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.June 26, 2024 | globenewswire.comAgile Therapeutics, Inc.: Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 16, 2024 | finanznachrichten.deSee More Headlines AGRX Stock Analysis - Frequently Asked Questions How were Agile Therapeutics' earnings last quarter? Agile Therapeutics, Inc. (NASDAQ:AGRX) announced its quarterly earnings data on Tuesday, November, 2nd. The specialty pharmaceutical company reported ($7.20) EPS for the quarter, beating the consensus estimate of ($7.60) by $0.40. The specialty pharmaceutical company earned $1.29 million during the quarter, compared to the consensus estimate of $1.49 million. When did Agile Therapeutics' stock split? Agile Therapeutics shares reverse split before market open on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Agile Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Agile Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD) and Arista Networks (ANET). Company Calendar Last Earnings11/02/2021Today12/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AGRX CUSIPN/A CIK1261249 Webwww.agiletherapeutics.com Phone(609) 683-1880FaxN/AEmployees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,470,000.00 Net Margins-36.24% Pretax Margin-36.24% Return on EquityN/A Return on Assets-147.37% Debt Debt-to-Equity RatioN/A Current Ratio0.56 Quick Ratio0.38 Sales & Book Value Annual Sales$19.98 million Price / Sales0.52 Cash FlowN/A Price / Cash FlowN/A Book Value($5.51) per share Price / Book-0.27Miscellaneous Outstanding Shares6,856,000Free Float6,822,000Market Cap$10.35 million OptionableNot Optionable Beta1.58 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:AGRX) was last updated on 12/12/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredEx-Lawyer turns $50k into $5 million tradingHe was a lawyer by day, secret trader by night...or in this case by lunch… With nothing but a laptop and a ...Investing Daily | SponsoredWant to Start Investing? It’s Easier Than You Think!Many people think you need a lot of money to start investing—but that’s simply not true. Andy Tanner, Rich ...The Cashflow Academy | SponsoredPrepare Now Before This Looming $2 Trillion D.C. ShockMillions of traders could get blindsided by this election-year shock on December 18th… And if you do nothin...Timothy Sykes | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agile Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agile Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.